这是一项IV期、多中心、开放标签、单臂研究，共入组了137例年龄在3个月至24个月以下的轻度至中度AD婴儿患者，评估了每天2次使用2% Eucrisa软膏的 ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for EUCRISA ® ointment, 2%, extending the lower age limit from 24 months ...

Credit: Pfizer. Eucrisa (crisaborole) ointment, 2%, is now approved for the treatment of mild to moderate atopic dermatitis in pediatric patients as young as 3 months old. Eucrisa (crisaborole ...

Top-line results from the CrisADe CARE 1 phase 4 trial showed that crisaborole ointment 2% (Eucrisa; Pfizer) was well-tolerated in children aged 3 months to less than 24 months with mild to ...

In 2016, crisaborole (Eucrisa) 2% ointment was approved as a non-steroidal option for treating atopic dermatitis in infants as young as 3 months of age.

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis ...

EUCRISA® (crisaborole) ointment, 2%, IMPORTANT SAFETY INFORMATION FROM THE U.S. PRESCRIBING INFORMATION . Do not use EUCRISA if you are allergic to crisaborole or any of the ingredients in EUCRISA.

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...

Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.

EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 ...

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...